ViaLase Raises $40 million Series C Financing

by

ViaLase, a leading medical technology company pioneering advancements in glaucoma treatment, has recently concluded a successful Series C financing round, securing approximately $40 million in gross proceeds. The funding was spearheaded by a new investor, with substantial backing from existing investors such as Venture Investors Health Fund, Arboretum Ventures, and Falcon Vision, supported by KKR, a prominent ophthalmology investment platform.

This latest round of financing will propel ViaLase’s ongoing efforts in advancing clinical, regulatory, and commercial milestones for its groundbreaking ViaLase® Laser*. If approved, the ViaLase Laser stands to become the world’s first femtosecond laser utilized in the treatment of primary open angle glaucoma (POAG), offering a revolutionary approach to glaucoma management.

Jim Adox, Executive Managing Director at Venture Investors, expressed confidence in ViaLase’s transformative potential, citing the company’s exceptional leadership, talented team, and innovative technology. Adox reaffirmed Venture Investors’ unwavering support for ViaLase, which dates back to their initial seed investment.

ViaLase’s CEO and Founder, Tibor Juhasz, PhD, underscored the significance of the investors’ backing, emphasizing the profound impact the ViaLase Laser could have on improving glaucoma treatment outcomes worldwide. Juhasz expressed gratitude for the support, resources, and guidance provided by the esteemed group of investors as ViaLase prepares to enter a new phase of commercialization.

At the heart of ViaLase’s groundbreaking technology is the ViaLase Laser, a fusion of femtosecond laser precision and micron-level image guidance. This innovative platform enables a noninvasive glaucoma treatment known as femtosecond laser image-guided high-precision trabeculotomy, or FLigHT. The FLigHT procedure offers physicians unparalleled accuracy and visibility in creating channels within the trabecular meshwork (TM), thereby effectively reducing intraocular pressure (IOP) through a noninvasive, nonsurgical approach.

Related Stories

Latest News Stories